<DOC>
	<DOCNO>NCT01934725</DOCNO>
	<brief_summary>BACKGROUND : In industrialized country considerable increase proportion stroke occur young age . Stroke young age cause marked disability bad thus long-standing socioeconomic consequence expose survivor 4-fold risk premature death compare background population . Up 50 % young patient ischemic stroke remain without definitive etiology disease despite extensive modern diagnostic work-up ( i.e . cryptogenic stroke ) . The group cryptogenic stroke include patent foramen ovale ( PFO ) abnormalities atrial septum heart concomitant finding . Population prevalence PFO high , 25 % , mechanisms PFO would associate causally ischemic stroke remain clarified . Moreover , scarce data clinical outcome , long-term risk new vascular event , prevention event patient . DESIGN : Searching Explanations Cryptogenic Stroke Young : Revealing Etiology , Triggers , Outcome ( SECRETO ) international prospective multicenter case-control study young adult ( age 18-49 ) present imaging-positive first-ever ischemic stroke undetermined etiology ( aim N=2000 ) . Patients include standardized diagnostic procedure ( brain MRI , image intracranial extracranial vessel , cardiac imaging , screen coagulopathies ) age- sex-matched healthy control 1:1 fashion . Up 45 study site worldwide need recruit plan participant population 3-year period . Neurovascular image echocardiography study , ECGs read centrally . AIMS : SECRETO involve five principal field investigation : ( 1 ) Stroke trigger clinical risk factor ; ( 2 ) Long-term prognosis ( new vascular event , functional psychosocial outcome ) ; ( 3 ) Abnormalities thrombosis hemostasis ; ( 4 ) Biomarkers e.g . inflammation , atherogenesis , endothelial function , thrombosis , platelet activation , hemodynamic stress characterize postulate cryptogenic stroke mechanism ; ( 5 ) genetic study , include genome-wide association candidate gene study well next-generation sequence approach . All analysis consider cardiac functional interatrial structural property possible mediator . Furthermore , SECRETO Family Study ( substudy ) aim collect extensive family history thrombotic event informative patient screen SECRETO main study collect genetic sample consent family member whole-genome sequencing . SIGNIFICANCE : SECRETO provide novel information clinical subclinical risk factor , transient chronic , predispose cryptogenic ischemic stroke young adult . This study also reveal long-term prognosis understudied patient population may discover new genetic background underlie disease mechanism provide potential target drug development .</brief_summary>
	<brief_title>Searching Explanations Cryptogenic Stroke Young : Revealing Etiology , Triggers , Outcome</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Brain Infarction</mesh_term>
	<mesh_term>Foramen Ovale , Patent</mesh_term>
	<criteria>PATIENTS : 1 . Age 18 49 stroke onset 2 . Patient hospitalize due firstever imagingpositive ischemic stroke undetermined etiology complete timely diagnostic testing . 1 . Baseline mandatory test obtain first week follow stroke onset , include : Brain MRI Routine blood test , include complete blood count , CRP , fast glucose , creatinine , aPTT , INR , total cholesterol , LDLcholesterol , HDLcholesterol , HbA1C , hemoglobin electrophoresis individual African origin 2 . Other baseline mandatory test obtain within first two week follow stroke onset , include : Imaging cervicocephalic artery CTA , MRA , DSA Transesophageal ( highly recommend ) transthoracic echocardiography 24hour Holter monitor continuous inhospital ECG monitoring automate arrhythmia detection least 24 hour Screening thrombophilia , include antiphospholipid antibody coagulopathies ( abnormal finding must retested mandatory 3month followup visit &gt; 12 week initial test &gt; 4 week cessation anticoagulation later time point ) ; mandatory test include anticardiolipin antibody , lupus anticoagulant , antiÎ²2glycoprotein antibody , factor V mutation ( aPC resistency rule ) , factor II mutation , homocysteine , antithrombin III , protein C , protein S 3 . No evidence current brain ischemia 4 . Current stroke due cerebral venous thrombosis complication subarachnoid hemorrhage , angiography , cardiac surgery 5 . Patient otherwise eligible study adherent followup ( eg nonresident ) concurrent disease affect outcome ( eg multiple sclerosis , cancer ) 6 . Informed consent obtain patient proxy . CONTROL SUBJECTS : 1 . Age 18 49 year 2 . Absence prior ischemic stroke ascertain use Questionnaire Verifying StrokeFree Status Exclusion Criterion : 1 . Informed consent obtain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Ischemic Stroke</keyword>
	<keyword>Brain Infarction</keyword>
	<keyword>Patent Foramen Ovale</keyword>
	<keyword>Stroke Young</keyword>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Cerebral Venous Thrombosis</keyword>
	<keyword>Pulmonary Embolism</keyword>
	<keyword>Deep Vein Thrombosis</keyword>
	<keyword>Subarachnoid Hemorrhage</keyword>
	<keyword>Prognosis</keyword>
	<keyword>Databases , Genetic</keyword>
</DOC>